Buzzacco Dominic M, Abdel-Rahman Mohamed H, Park Stanley, Davidorf Frederick, Olencki Thomas, Cebulla Colleen M
Department of Ophthalmology and Vision Science, The Ohio State University, Columbus, Ohio, USA.
Open Ophthalmol J. 2012;6:49-53. doi: 10.2174/1874364101206010049. Epub 2012 Jun 25.
To report the tumor, patient, and treatment characteristics of long-term metastatic uveal melanoma survivors.
A non-comparative, retrospective case series of patients from a single institution surviving >24 months with metastatic uveal melanoma (UM).
Nine patients met the study criteria and their charts were reviewed. The mean age at diagnosis of UM was 44.1 years (SD +/- 14.4 years). Initial treatment modalities included enucleation (67%), brachytherapy (22%), and proton beam radiation (11%). The average time from primary tumor diagnosis to detection of metastasis was 125.9 months (SD +/- 95 months). The most common location for initial metastasis was the liver. All patients underwent treatment for metastatic disease including systemic therapy, surgical resection, and isolated hepatic perfusion. The majority of patients received treatment with a tyrosine kinase inhibitor (sorafenib, sunitinib, and/or imatinib). The median survival with metastasis was 51 months (range 27-123 months). Patients had a long disease-free interval before presentation of metastatic disease.
A small subset of patients with metastatic UM has prolonged survival. Identification of these patients may be helpful for future clinical trial design.
报告长期转移性葡萄膜黑色素瘤幸存者的肿瘤、患者及治疗特征。
一项来自单一机构的非对照性回顾性病例系列研究，纳入转移性葡萄膜黑色素瘤（UM）存活超过24个月的患者。
9例患者符合研究标准并对其病历进行了回顾。UM诊断时的平均年龄为44.1岁（标准差±14.4岁）。初始治疗方式包括眼球摘除术（67%）、近距离放射治疗（22%）和质子束放疗（11%）。从原发性肿瘤诊断到转移灶检测的平均时间为125.9个月（标准差±95个月）。初始转移最常见的部位是肝脏。所有患者均接受了转移性疾病的治疗，包括全身治疗、手术切除和孤立性肝灌注。大多数患者接受了酪氨酸激酶抑制剂（索拉非尼、舒尼替尼和/或伊马替尼）治疗。转移后的中位生存期为51个月（范围27 - 123个月）。患者在出现转移性疾病之前有较长的无病间期。
一小部分转移性UM患者生存期延长。识别这些患者可能有助于未来的临床试验设计。
